LianBio (NASDAQ:LIAN) Expected to Post Earnings of -$0.33 Per Share

Equities analysts expect that LianBio (NASDAQ:LIAN) will report earnings per share of ($0.33) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for LianBio’s earnings, with the lowest EPS estimate coming in at ($0.53) and the highest estimate coming in at ($0.18). The business is expected to announce its next quarterly earnings results on Thursday, March 10th.

According to Zacks, analysts expect that LianBio will report full year earnings of ($4.51) per share for the current fiscal year, with EPS estimates ranging from ($6.16) to ($2.75). For the next year, analysts forecast that the business will post earnings of ($1.21) per share, with EPS estimates ranging from ($1.40) to ($0.96). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow LianBio.

LianBio (NASDAQ:LIAN) last announced its earnings results on Wednesday, December 8th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.06).

LIAN has been the subject of several analyst reports. Jefferies Financial Group began coverage on shares of LianBio in a research note on Friday, November 26th. They issued a “buy” rating and a $24.00 target price for the company. Raymond James began coverage on shares of LianBio in a report on Wednesday, November 24th. They issued an “outperform” rating and a $27.00 price target on the stock. Bank of America began coverage on shares of LianBio in a report on Friday, November 26th. They issued a “buy” rating on the stock. Finally, The Goldman Sachs Group began coverage on shares of LianBio in a report on Friday, November 26th. They issued a “neutral” rating and a $18.58 price target on the stock.

Shares of LIAN stock traded down $0.13 on Friday, hitting $4.98. The stock had a trading volume of 110,450 shares, compared to its average volume of 109,553. The business has a 50 day simple moving average of $9.16. LianBio has a 52-week low of $4.33 and a 52-week high of $16.37.

LianBio Company Profile

LianBio is a cross-border biotechnology company dedicated to bringing medicines to patients principally in China and other major Asian markets. LianBio is based in SHANGHAI, China.

Featured Story: What are the advantages of the Stochastic Momentum Index?

Get a free copy of the Zacks research report on LianBio (LIAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.